XNAS
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | -0.14 | -0.15 | -7.14% | $0 | ❌ Miss | +0.00% | -7.09% | — |
| 2026-03-13 | Q4 2025 | -0.12 | -0.13 | -8.33% | $0 | ❌ Miss | +0.00% | -5.52% | +12.76% |
| 2025-11-12 |
| Q3 2025 |
| -0.13 |
| -0.14 |
| -7.69% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-13 | Q2 2025 | -0.12 | -0.14 | -16.67% | $0 | ❌ Miss | +0.00% | +14.44% | +31.85% |
| 2025-03-27 | Q4 2024 | -0.11 | -0.13 | -18.18% | $0 | ❌ Miss | +4.68% | +4.32% | +14.75% |
| 2024-08-12 | Q2 2024 | -0.11 | -0.12 | -9.09% | $0 | ❌ Miss | +0.98% | +8.54% | +5.37% |
| 2024-03-07 | Q4 2023 | -0.10 | -0.09 | +10.00% | $0 | ✅ Beat | — | — | — |
| 2023-08-10 | Q2 2023 | — | -0.07 | — | $0 | — | +1.04% | -10.42% | -0.78% |
Showing last 8 quarters.